HOME >> BIOLOGY >> NEWS
New strategy for treating allergic disorders

Ghent − Oral intake of allergens or auto-antigens via the lactic acid bacterium Lactococcus lactis might be a new strategy for treating various kinds of auto-immune and allergic disorders. VIB researchers associated with Ghent University, in collaboration with the Academic Medical Center (AMC) in Amsterdam, have shown that auto-antigens or allergens can be administered orally via the lactic acid bacterium. Based on this principle, which has been patented by VIB, ActoGeniX − a spin-off from VIB and Ghent University − is already developing a variety of biopharmaceutical medicines for a range of clinical indications.

The immune system

Every day our immune system combats harmful substances and micro-organisms that seek to penetrate our body. However, if our immune system is not working properly, we are subject to a variety of diseases. In the case of auto-immune diseases, the immune system no longer distinguishes between our bodys own substances and foreign substances and begins to attack our own tissues and organs. In other cases, the immune system responds mistakenly to harmless substances, such as the house dust mite, milk products, or pollen. This inappropriate immune system reaction to contact with such substances (allergens) is called an allergy. Today, 20% of the European population suffers from an allergy, which is twice as many sufferers compared to 15 years ago.

Lactococcus as supplier of remedies

In its natural form, the lactic acid bacterium (Lactococcus lactis) is a well-known food bacterium that has been used since time immemorial to convert milk into cheese and yoghurt. In the battle against chronic intestinal diseases, VIB researchers have been using L. lactis as a producer of a drug against gastroenteritis. The initial results of the clinical trials are promising.

Now, the bacterium is also being used to fight other disorders. There are a number of active substances for the treat
'"/>

Contact: Ann Van Gysel
ann.vangysel@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
1-Aug-2007


Page: 1 2

Related biology news :

1. Does EPA have an adequate strategy to oversee nanotechnologies?
2. High blood pressure medication strategy proves effective in Hispanic women
3. Rutgers: GM/GMO/Biotech crop containment strategy
4. Scientists identify new strategy for preventing acute and chronic brain disease
5. International risk research strategy and funding needed for nanotech safety
6. Study shows metabolic strategy of stressed cell
7. Trojan horse strategy defeats drug-resistant bacteria
8. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
9. Drug strategy makes cancer genes get lost in translation
10. Researchers develop new strategy for the treatment of CML
11. Nanotech safety needs specific government risk research strategy and funding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):
(Date:5/24/2016)... ... , ... Last week, Callan Capital, an integrated wealth management firm specializing in ... San Diego Life Science event at the Estancia La Jolla Resort and Spa. , ... speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former ...
(Date:5/23/2016)... 2016 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2016. The cash dividend of $0.24 per ... to stockholders of record as of the close of business ... to approval of the Board of Directors and may be ...
(Date:5/23/2016)... ... 23, 2016 , ... Foresight Institute , a leading ... for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, named ... for experiment and the other for theory in nanotechnology. Prof. Markus J. Buehler, ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or ... way to treat the disease. Surviving Mesothelioma has just posted an article on the ... Korean institutions based their mesothelioma study on the fact the Manumycin A, a derivative ...
Breaking Biology Technology:
Cached News: